Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
| Conditions: | Malignant Mesothelioma |
| Start Date: | June 1, 2006 |
| Phase: | Phase II |
| Status: | Completed |
| NCT ID: | NCT00365053 |
| Study Type: | Interventional |
| Intervention: | Drug: belinostat|Genetic: reverse transcriptase-polymerase chain reaction|Other: laboratory biomarker analysis |
| Study Design: | Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | California Cancer Consortium|National Cancer Institute (NCI) |
| Ages: | Adult|Senior |
| Enrollment: | 37 |
| Funded By: | Other|NIH |
| First Received: | August 16, 2006 |
| End Date: | |
| Last Updated: | October 11, 2010 |
| Last Verified: | October 1, 2010 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
